Search Results

Prime-boost vaccine regimen in development at the Janssen Pharmaceutical Companies currently in Phase I and II clinical studies in Europe, U.S. and Africa

Innovative Medicine

September 4, 2015

U.S. FDA Grants Priority Review to Janssen for Daratumumab as a Treatment for Multiple Myeloma

If approved, daratumumab will offer a new option for double refractory, heavily pre-treated patients

Innovative Medicine

August 27, 2015

Data Published in The New England Journal of Medicine Show Single-Agent Daratumumab Demonstrated a 36 Percent Overall Response Rate and Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients

Study results also showed 65 percent of responding patients remained in remission at 12 months

Innovative Medicine

August 21, 2015

Janssen Submits European Extension Marketing Authorisation Application for Paliperidone Palmitate Once-Every-Three-Months Formulation

First long-acting treatment to be administered four times a year for the treatment of schizophrenia in adults

Innovative Medicine

July 24, 2015

Janssen Submits Supplemental New Drug Application to U.S. FDA for All-Oral, Once-Daily OLYSIO® (Simeprevir) in Combination with Sofosbuvir

Filing Supported by Data from the Phase 3 OPTIMIST-1 and -2 Clinical Trials Evaluating OLYSIO® Combination Therapy in Hepatitis C Patients with and without Cirrhosis

Search Results

No Results

Search Results

You are now leaving jnj.com/innovativemedicine